You are here: Industry Insights > Cervical Cancer

News List

HPV Vaccination Is Lowering U.S. Cervical Cancer Rates drugs
May 20, 2021
In a finding that offers the first evidence that the human papillomavirus (HPV) vaccine is indeed protecting women from cervical cancer, new research shows cases in the United States have slowly but steadily declined over the last decade and a half.
Libtayo Monotherapy Trial in Advanced Cervical Cancer Stopped Early for OS Positive Result americanpharmaceuticalreview
March 22, 2021
Regeneron Pharmaceuticals and Sanofi announced positive results demonstrating an overall survival (OS) benefit from the Phase 3 trial investigating the PD-1 inhibitor Libtayo® (cemiplimab) monotherapy compared to chemotherapy, in patients previously ...
Libtayo® improves overall survival in advanced cervical cancer patients europeanpharmaceuticalreview
March 16, 2021
A Phase III trial evaluating Libtayo® (cemiplimab) monotherapy in advanced cervical cancer has been stopped early due to a positive result on overall survival.
Sanofi, Regeneron’s Libtayo improves survival in cervical cancer patients pharmatimes
March 15, 2021
Sanofi and Regeneron’s PD-1 inhibitor Libtayo has demonstrated positive overall survival (OS) results in a Phase III trial in advanced cervical cancer.
Merck Announces Update on the INTR@PID Clinical Program Including Lung 037 Study prnasia
January 21, 2021
Merck, a leading science and technology company, announced an update on the Phase III INTR@PID Lung 037 study and the extensive INTR@PID clinical trial program for the potential first-in-class investigational bifunctional immunotherapy bintrafusp alfa ...
Innovent Announces First Patient Dosed in Phase 2 Pivotal Trial of IBI310 (CTLA-4) combined with TYVYT® (sintilimab injection) for the treatment of second-line or above Advanced Cervical Cancer prnasia
December 11, 2020
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announces that the first ...
Immunotherapies to treat cervical cancer show promise in Phase II trials europeanpharmaceuticalreview
October 16, 2020
Novel programmed cell death protein 1 immunotherapies for cervical cancer have demonstrated success in two Phase II clinical trials in the US.
Agenus Receives Fast Track Designation for Cervical Cancer Treatment americanpharmaceuticalreview
March 17, 2020
Agenus announced the U.S. Food and Drug Administration (FDA) has granted Agenus Fast Track designation for investigation of balstilimab [PD-1] in combination ...
Tessa Therapeutics collaborates with MSD to treat Cervical Cancer biospectrumasia
April 16, 2019
The collaboration will evaluate the safety and efficacy of Tessa's armored human papillomavirus-specific T cell (HPVST) therapy combined with MSD's……
HPV vaccine to thank for 89% decline in cervical cancer pharmatimes
April 10, 2019
A new analysis has found that human papillomavirus (HPV) vaccination of 12 and 13 year old girls has led to an 89% decline in cases of cervical cancer in Scotland.

Previous page 1 2 3 4 Next page